SLC16A8

Across TCGA pan-cancer cohorts, SLC16A8 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SLC16A8 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SLC16A8 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC16A8 expression acts as an unfavorable survival marker.

HNSC, LUSC, and BLCA are the cancer types where SLC16A8 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.058	0.751	<.001	48	view →
LUSC	DFS	Median	II,III,IV	0.199	0.748	.006	6	view →
BLCA	DFS	Median	All	0.228	0.627	.029	6	view →
SKCM	DFS	Median	IV	0.036	0.433	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SLC16A8–HNSC (OS)

Open the HNSC breakdown →